Autoinjectors Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 19.2% during the forecast period (2022-2029).
By Type, By Technology, By Therapy, By End-User, and By Region
Report Insights Covered
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region
Largest Market Share
To Download free sample click here
Autoinjectors are self-injectable devices that can deliver drugs through subcutaneous or intramuscular routes. They hold prefilled syringes or cartridges which are driven by a spring system. The major advantages of this device are comfortable self-administration, enhanced patient compliance, decreased anxiety, and dosage precision.
The global autoinjectors market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of chronic diseases such as cancer and diabetes, rising patient healthcare expenditure and growing research and development activities.
An increasing number of chronic diseases such as cancer and diabetes drives the market growth
The growing number of chronic diseases, such as cancer and diabetes, boosts the autoinjectors market worldwide. According to the World Health Organization (WHO), a globally agreed target is to halt the advancement in diabetes and obesity by 2025. Approximately 422 million people worldwide have diabetes, the prevalence living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. The number of cases and the majority of diabetes have been steadily growing over the past few years. The rising number of diabetes patients leads to increasing demand for autoinjectors to manage the disease. The autoinjectors deliver the drug to diabetes patients. It provides easy and comfortable administration.
In September 2021, Owen Mumford Pharmaceutical Services introduced its new Aidaptus autoinjector platform. The new device is a 2-step, spring-powered, single-use autoinjector designed to accommodate 1 mL and 2.25 mL prefilled glass syringes in the same base device. Also, in May 2022, Halozyme Therapeutics, Inc. acquired Antares Pharma, Inc. The combination of Halozyme and Antares will create a leading drug delivery and specialty product company. The Antares business consists of a best-in-class, differentiated, royalty revenue-generating autoinjector platform business that offers broad licensing opportunities, and a commercial business, with three proprietary commercial products.
The side effects of autoinjectors will hamper the growth of the market
However, the side effects of autoinjectors include Redness, pain, or swelling at the injection site. Constipation may also occur. Additionally, symptoms of a serious allergic reaction include rash, severe dizziness, itching/swelling (especially of the face/tongue/throat), and trouble breathing.
COVID-19 Impact Analysis
The COVID-19 epidemic has quickened the trend of self-injection, allowing patients to become more active and in control of their treatment. The direction has promoted newer technologies in the autoinjectors market for enhanced injection speed regulation, injection site pain, and treat anxiety.
In addition, the new products launched by key players are driving the market during the COVID-19 pandemic. For instance, in April 2020, Teva Pharmaceuticals USA, Inc. announced that the autoinjector device for AJOVY (fremanezumab-vfrm) injection is available in the United States. AJOVY is implied for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options. Also, in September 2021, Novartis reported data from an international Phase IIIb study, which delivered treatment with Cosentyx (secukinumab) 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high effectiveness and proper administration in adults with mild to severe plaque psoriasis1. These data were presented at the European Academy of Dermatology and Venereology’s 30th Anniversary Congress.
Moreover, the broader drug delivery market has historically shown consistent, healthy growth, despite the grim realities of the pandemic. As the world begins to recover from the long-lasting effects of COVID-19 and approaches a period of greater stability and normality, markets are expected to flourish.
The disposable autoinjectors segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The disposable autoinjectors segment accounts for the largest market share. As per the article published in Saudi Pharmaceutical Journal in October 2021, More than 20 pharmaceutical companies have developed nearly 80 autoinjectors. Nearly 50 drugs are developed as combination products for administration using autoinjectors. Among these, 62% of the autoinjectors are disposable.
In addition, the market players are developing advanced solutions for the autoinjectors market. For instance, in May 2022, Owen Mumford designed the Aidaptus disposable autoinjector platform. Aidaptus is a 2-step, single-use autoinjector with a versatile design that accommodates 1mL and 2.25mL prefilled glass syringes in the same base device. It also features plunger sensing technology with a self-adjusting plunger rod that automatically adapts to the individual plunger positions and different fill volumes in each syringe, requiring no change parts. The autoinjector is also able to accommodate a unique variety of drug viscosities.
Also, the BD Physioject Disposable Autoinjector 1 mL is a commercially proven, easy-to-use, button-activated, disposable autoinjector for treating chronic diseases. DAI is a three-step, button-activated autoinjector among the first modern autoinjectors to be commercialized for home injection. Moreover, the Flexi-Q EAI is a 2-step, fully disposable autoinjector for drugs in 1 mL or 2.25 mL prefilled syringes (PFS). This easy-to-use and single-use autoinjector features passive needle shielding and allows better patient safety.
North America region holds the largest market share of the global Autoinjectors market
North America dominates the market for autoinjectors and is expected to show a similar trend over the forecast period. The market is driven by factors such as FDA approval for products, regional key players, advanced healthcare facilities and rising chronic diseases.
The product launches by key players are driving the autoinjectors market in the North American region. For instance, in June 2020, Mylan N.V. and Biocon Ltd. announced the USFDA approval of the New Drug Application for Semglee (insulin glargine injection) in the vial and pre-filled pen forms to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type-1 diabetes. Semglee includes the same amino acid sequence as Lantus from Sanofi and is licensed for the same indications. Also, in August 2021, Xeris Pharmaceuticals introduced its Gvoke HypoPen glucagon injection to treat severe hypoglycemia. The autoinjector is developed to treat severe hypoglycemia in adults and kids with diabetes that are aged two years and older. The premixed autoinjector has no visible needle and has a reliable delivery method. According to the company, 99% of people could use the device correctly, and 99% of adults and 100% of kids had their blood sugars raised to safe levels.
Moreover, in May 2022, Jabil Healthcare, a division of Jabil Inc., launched the Qfinity autoinjector platform, an easy, reusable and modular solution for subcutaneous drug self-administration at a lower cost than market alternatives supporting the emerging prioritization of sustainable drug delivery within the pharmaceutical enterprises.
The autoinjectors market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Kaléo, AbbVie, Amgen, Biogen Idec, AstraZeneca, Mylan, Pfizer, Teva Pharmaceuticals, Biogen, Eli Lilly, Merck & Co, Sandoz, Johnson &Johnson, YpsoMed, and Becton Dickinson and Company, among others. The major players are adopting several growth strategies such as Type launches, acquisitions, and collaborations, contributing to the global autoinjectors growth.
Biogen Idec is an independent biotechnology company founded in 1978. It discovers, develops and delivers to patients worldwide innovative therapies for treating neurodegenerative diseases, hemophilia and autoimmune disorders.
AVONEX PEN: It is the first intramuscular autoinjector approved for MS, incorporating a smaller needle and easier administration to help patients reduce anxiety about AVONEX self-injection.
The global autoinjectors market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
What is the Projected CAGR value of the Autoinjectors Market?
Autoinjectors Market is expected to grow at a CAGR of 21.6% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Autoinjectors Market during 2022-2029
Which is the fastest growing region in the Autoinjectors Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
Get your free sample proposal with a single click!